Stem Cell Reconstructive Market Applications, Types and Future Outlook Report 2020-2027 – Bulletin Line

New Jersey, United States,- The research report on Stem Cell Reconstructive market comprises of insights in terms of pivotal parameters such as production as well as the consumption patterns alongside revenue estimations for the projected timeframe. Speaking of production aspects, the study offers an in-depth analysis regarding the manufacturing processes along with the gross revenue amassed by the leading producers operating in this business arena. The unit cost deployed by these producers in various regions during the estimated timeframe is also mentioned in the report.

Significant information pertaining to the product volume and consumption value is enlisted in the document. Additionally, the report contains details regarding the consumption graphs, Individual sale prices, and import & export activities. Additional information concerning the production and consumption patterns are presented in the report.

In a word, the Stem Cell Reconstructive Market report provides major statistics on the state of the Stem Cell Reconstructive industry with a valuable source of guidance and direction for companies and individuals interested in the market. In the end, Stem Cell Reconstructive Market report delivers a conclusion which includes Research Findings, Market Size Evaluation, Global Market Share, Consumer Needs along with Customer Preference Change, Data Source. These factors will raise the growth of the business overall.

Regions Covered in the Global Stem Cell Reconstructive Market:

The Middle East and Africa (GCC Countries and Egypt)

North America (the United States, Mexico, and Canada)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report:

Accurate market size and CAGR forecasts for the period 2020-2026

Identification and in-depth assessment of growth opportunities in key segments and regions

Detailed company profiling of top players of the global Stem Cell Reconstructive market

Exhaustive research on innovation and other trends of the global Stem Cell Reconstructive market

Reliable industry value chain and supply chain analysis

Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report offers a complete company profiling of leading players competing in the global Stem Cell Reconstructive marketwith a high focus on the share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Stem Cell Reconstructive market.

Reasons to Buy the Report:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Link:
Stem Cell Reconstructive Market Applications, Types and Future Outlook Report 2020-2027 - Bulletin Line

‘Self-eating’ stem cell process may be the key to new regenerative therapies – Penn Today

The self-eating process in embryonic stem cells known as chaperone-mediated autophagy (CMA) and a related metabolite may serve as promising new therapeutic targets to repair or regenerate damaged cells and organs,Penn Medicineresearchers show in a new study published online inScience.

Human bodies contain more than 200 different types of specialized cells. All of them can be derived from embryonic stem (ES) cells, which relentlessly self-renew while retaining the ability to differentiate into any cell type in adult animals, a state known as pluripotency. Researchers have known that the cells metabolism plays a role in this process; however, it wasnt clear exactly how the cells internal wiring works to keep that state and ultimately decide stem cell fate.

The new preclinical study, for the first time, shows how the stem cells keeps CMA at low levels to promote that self-renewal, and when the stem cell is ready, it switches that suppression off to enhance CMA, among other activities, and differentiate into specialized cells.

Its an intriguing discovery in the field of stem cell biology and for researchers looking to develop therapies for tissue or organ regeneration, says senior authorXiaolu Yang, a professor of cancer biology at the Abramson Family Cancer Research Institute in the Perelman School of Medicine. We reveal two novel ways to potentially manipulate the self-renewal and differentiation of stem cells: CMA and a metabolite, known as alpha-ketoglutarate, that is regulated by CMA. Rationally intervening or guiding these functions could be a powerful way to increase the efficiency of regenerative medicine approaches.

This story is by Melissa Moody. Read more at Penn Medicine News.

See the article here:
'Self-eating' stem cell process may be the key to new regenerative therapies - Penn Today

A breakthrough: Stem cell therapy cures Covid-19 The Manila Times – The Manila Times

SIX patients who were suffering from the acute coronavirus disease 2019 (Covid-19) were cured through the stem cell technology using blood from preserved umbilical cords.

The revolutionary method of curing the dreaded virus, which originated in China and has spread worldwide, was announced by The Medical City (TMC) hospital in Pasig City.

Health Secretary Francisco Duque 3rd was informed of the breakthrough in treating the pandemic illness through a letter sent by Dr. Eugenio F. Ramos, TMC president and chief executive officer, on Thursday, July 23.

Our government, particularly the Department of Health, can take pride in the fact that the Philippines is not behind at all in innovative practice in medicine, said Ramos in his letter to Duque.

The TMC has been experimenting with stem cell therapy since 2015 through its Institute of Personalized Molecular Medicines stem cell program.

The stem cell experiment was made on seven Covid-19 patients who were so ill they were about to be intubated.

Intubation means inserting a tube into the patients mouth that reaches the trachea to allow him/her to breathe through a lung machine.

Six of the seven patients had recovered, the TMC said; one was so ill he died during the procedure.

As I told you this morning, we would have wanted to complete at least 10 Covid-19 cases before informing you, but it might be taken against us if we kept this knowledge from the public too long while patients are dying and no single drug seems to work, Dr. Ramos told Duque.

Ramos simplified for the public how the stem cell therapy works:

Stem cells are very young cells from the body that can be differentiated into whatever cell lines (lung, heart, kidney, liver, skin, etc.) that the body needs when it needs them, e.g., when an organ is injured or deteriorates. Stem cells can be triggered or infused to do [repair] work.

In severe Covid-19 cases, what triggers a cascade of inflammatory cells (called cytokines) is the injury caused by the virus. The lungs, in particular, become inflamed and the respiratory function rapidly deteriorates leading to death.

Before the cascade happens in which case the patient is in a severe condition probably requiring intubation the infusion of mesenchymal stem cells collected [from] the umbilical cord and grown in [the regenerative medicine laboratory of TMC into the patients veins, takes place.

A total of four infusions are given over a short period of a few days. These messenchymal stem cells rally the cells in the lungs to fight the cytokines.

In short, the stem cells from the umbilical cord produce new cells to replace those damaged by the virus in the lungs, leading to the patients recovery.

The umbilical cord is rich in nutrients to rebuild destroyed tissues, according to Ramos.

TMCs stem cell program also makes use of bone marrow taken from a patients spine to cure cancer.

But the bone marrow stem cell is also used to delay the aging process in elderly patients.

TMC had the most number of bone marrow transplantation for blood cancers, with more than 90 percent survival rate, said Dr. Ramos.

Since 2015, a total of 112 patients have enrolled in TMCs regenerative medicine program.

Of the total, 57 percent were cancer patients and 43 percent were non-cancer patients, said TMCs Dr. Michelle Joy Baldorado-de Vera.

Oncologists (doctors who specialize in cancer) are part of the regenerative medicine program Alan Olavere, Marina Chua-Tan and Josephine Tolentino.

Other members are hematologists (blood doctors) Norma Ona and Alma Calavera, neurologists John Tiongson and Marc Joseph Buensalido, and immunologist Michelle de Vera.

Dr. Sam Bernal, a Filipino American who grew up in the United States, is a consultant to the program.

Bernal is a molecular scientist and an oncologist who has been into stem cell technology for decades.

He was part of the foreign group that was tapped by the government for technology transfer.

Former Health secretary Alfredo Bengzon, who is a part owner of TMC, engaged Bernal to pioneer stem cell therapy in the country.

TMC has had foreign patients who underwent stem cell therapy, but refuses to disclose their number.

As is the norm among Filipinos who have the crab mentality, TMCs stem cell program has been criticized by fellow doctors.

Weve been defending the program from the outset, said Dr. Ramos.

But its not only TMC that has been into stem cell therapy; the other hospitals are the Makati Medical Center and the governments National Kidney and Transplant Institute.

See the article here:
A breakthrough: Stem cell therapy cures Covid-19 The Manila Times - The Manila Times

Hemophilia Treatment Market Size & Share 2020 Analysis and Oulook Report till 2026 – Northwest Trail

Facts & Factors,leading market research and the consulting firm added the latest industry outlook report on "Hemophilia Treatment Market By Product (Desmopressin, Antifibrinolytic Agents, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates), By Disease (Hemophilia A, Hemophilia B, Hemophilia C, and Others), By Therapy (Replacement Therapy, ITI Therapy, Gene Therapy, and Antibody Therapy), By Treatment Type (On-demand and Prophylaxis), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others), And By Region: Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 20202026" consisting of 190+ pages during the forecast period 2020 to 2026 and the Hemophilia Treatment Market report offers comprehensive research updates and information related to market growth, demand, and opportunities in the Hemophilia Treatment Market.

This specialized and expertise oriented industry research report scrutinizes the technical and commercial business outlook of the Hemophilia Treatment market. The report analyzes and declares the historical and current trends analysis of the titanium dioxide industry and subsequently recommends the projected trends anticipated to be observed in the Hemophilia Treatment market during the upcoming years.

The report covers market size status and forecast, value chain analysis, market segmentation of Top countries in Major Regions, such as North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, by type, application, and marketing channel. In addition, the report focuses on the driving factors, restraints, opportunities, and PEST analysis of major regions.

Request an Exclusive Free Sample Report of Hemophilia Treatment Market: http://www.fnfresearch.com/sample/global-hemophilia-treatment-market-by-product-desmopressin-antifibrinolytic-790

(The sample of this report is readily available on request).

Benefits of Requesting a FREE Sample Report Before Purchase:

(Note: The sample of this report is updated with COVID-19 analysis before delivery)

Some of Following Top Market Players Profile Included in This Report:

Hemophilia Treatment Market Analysis by Leading Market Players

Leading top market players in the Hemophilia Treatment market are analyzed in the report along with their business overview, operations, geographical locations, financial analysis, SWOT profile, and Carbon Black products & services.

COVID-19- Current Scenario, Potential Impact, and Strategic Situation Analysis

Various communities and companies are doing their best to function and perform, and eventually cope with the challenges raised by COVID-19 pandemic. The COVID-19 pandemic had a negative impact on the market size for the year 2020, with small and medium scale companies struggling to sustain their businesses in the near term future. Industry leaders are now focusing to create new business practices to deal with crisis situations like COVID-19 pandemic.

This study especially analyses the impact of the Covid-19 outbreak on the Hemophilia Treatment market, covering the supply chain analysis, impact assessment to theHemophilia Treatment market size growth rate in several scenarios, and the measures to be undertaken by Hemophilia Treatment companies in response to the COVID-19 pandemic.

Enquire About COVID-19 Updates for This Report: http://www.fnfresearch.com/inquiry/global-hemophilia-treatment-market-by-product-desmopressin-antifibrinolytic-790

The Hemophilia Treatment market research report offers valuable insights pertaining to the revenue segmentation, business summary, and product offerings of the foremost market players. The study also estimates the expansion of the well-known market players through SWOT study. Also, it considers the most recent developments in the market whilst estimating the growth of major market players. Furthermore, in the Hemophilia Treatment market size report, the main product category and segments along with its sub-segments of the Keyword market are elaborated.

The Hemophilia Treatment market analysis research report is drafted on the basis of a brief assessment and huge data collected from the Hemophilia Treatment market. The data collected include current industry trends and requirements associated with services & manufacturing goods.

The report on Hemophilia Treatment market worth segments and defines the Hemophilia Treatment market considering the in-detailed forecasts and study of the market size. The report further includes various figures, data tables, and in-depth TOC on the Hemophilia Treatment market.

Request Customized Copy of Report @ http://www.fnfresearch.com/customization/global-hemophilia-treatment-market-by-product-desmopressin-antifibrinolytic-790

(We customize your report according to your research need. Ask our sales team for report customization.)

What Hemophilia Treatment Market research report offers?

About Us:

Facts & Factors is a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background. Our wide-ranging database offers statistics and detailed analysis of different industries worldwide that help the clients in achieving sustainable progress. The well-organized reports help clients in developing strategies and making informed business decisions.

Contact Us:

Facts & Factors

A 2108, Sargam,

Nanded City,

Sinhagad Road,

Pune 411041, India

USA: +1-347-989-3985

E-Mail: sales@fnfresearch.com

Web: http://www.fnfresearch.com

See the article here:
Hemophilia Treatment Market Size & Share 2020 Analysis and Oulook Report till 2026 - Northwest Trail

Mum whose husband died of coronavirus shares heartbreaking video of one-year-old son saying Dada as his fir – The Irish Sun

A MUM whose husband died of coronavirus complications has shared a heartbreaking video of their one-year-old son saying "Dada" as his first words.

Broadway star Nick Cordero tragically passed away last month - leaving behind his devastated wife Amanda Kloots-Larsen and their baby son Elvis.

5

Posting on her Instagram page, Amanda shared an emotional clip of Elvis pointing at a picture of his father and saying "Dada right there".

In the video, the tot reaches for the picture light which is covered in images of his dad and gives it a kiss.

Alongside the video, Amanda wrote: "[Elvis] hasnt seen Nick since March 30th.

"The fact that he still knows who his Dada is, point to him and give him a kiss to me is amazing."

5

5

Earlier this week, Amanda revealed on social media that her and Elvis are moving into the house in LA she had purchased with her late husband.

Nick tragically caught coronavirus when he was packing up his home in New York - and was originally misdiagnosed with pneumonia when he returned to Los Angeles.

Doctors were not onlyforced to amputate Nick's right leg as a result of blood clots, but the Broadway star also had to undergo stem cell treatment to strengthen his lungs.

But on July 5, 2020Nick sadly passed away after 91 days in hospital.

5

5

Explaining how she was putting on a "brave face" for her son, Amanda wrote: "Im not expecting this to be easy, in fact I think it will be very hard, but Im going into it knowing I need to be strong.

"I have to find my new normal, at least whatever that is for Elvis and I right now. I know Nick will be with us.

"He wanted to live in this house more than anything so Ill put lots of family photos up and make sure his presence is with us."

Amanda's video of Elvis' first words has been viewed by over 296,000 users on Instagram - and it left fans in tears.

"Beautiful moment," one replied. "Thank you for sharing with us."

Another added: "My heart is happy and sad at the same time."

"How precious," a third wrote. "He clearly remembers his Dadda."

For more real life stories, this mum's pregnancy made her so sick she felt suicidal and asked for an abortion.

And this mum thought her daughter would be safe at nursery but an accident almost blinded her & she needed five-hour eye surgery.

Plus this woman grew up thinking her mum tried to kill her in a fire which left her with horrific scars but she wont lie to my son about the past.

More:
Mum whose husband died of coronavirus shares heartbreaking video of one-year-old son saying Dada as his fir - The Irish Sun

Clinical Laboratory Services Market – Detailed Analysis of Current and Future Industry Figures till 2027 | Global Players Mayo Foundation for Medical…

Clinical Laboratory Services Market

Data Bridge Market Research (DBMR) has published a latest market research report on Global Clinical Laboratory Services Market . The global report is prepared in collaboration with the leading industry experts & dedicated research analyst team to provide an enterprise with in-depth market insights & help them to take crucial business decisions. This report covers current market trends, opportunities, challenges & detailed competitive analysis of the industry players in the market.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-clinical-laboratory-services-market&rp

This Clinical Laboratory Services market report practices the latest tools and techniques for researching, analysing and assembling data and information. The market study conducted in this large scale market report spans diverse markets in accord with the requirement of Healthcare industry and scoop out the most promising solutions and in-depth information about the market trends.

Market Analysis and Insights:Global Clinical Laboratory Services Market

Clinical laboratory services market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.2% in the forecast period of 2020 to 2027 and expected to reach USD 217,941.33 million by 2027 from USD 134,692.52 million in 2019. Rising demand for early and accurate disease diagnosis is the factors for the market growth.

The major players covered in theClinical Laboratory Services MarketareMayo Foundation for Medical Education and Research (MFMER), Laboratory Corporation of America Holding, Quest Diagnostics Incorporated, Spectra Laboratories (A Subsidiary of Fresenius Medical Care AG & Co. KGaA), DaVita Inc., Eurofins Scientific, UNILABS, SYNLAB International GmbH, MIRACA HOLDINGS Inc., Sonic Healthcare, ACM Global Laboratories, amedes Group, LifeLabs, Alere (A Subsidiary of Abbott), Charles River, Siemens Healthineers AG, BioReference Laboratories, Inc., NeoGenomics Laboratories, Inc., KingMed Diagnostics, Genomic Health, among other players domestic and global.Clinical laboratory services market share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-clinical-laboratory-services-market&rp

Clinical laboratory services is playing significant role to enable doctors to make appropriate clinical and diagnostic decisions across various levels of health care services. Increasing demand for diagnostic tests is augmenting the market growth as they are used for clinical diagnoses tests.

Clinical laboratory services demand has been increased with rising infectious diseases worldwide as compared to the past few years which will accelerate the market growth. Clinical diagnostic advancement methods for diagnoses of diseases in the clinical laboratory. For instance, Technological advancement in the clinical diagnostic methods have made diagnostic tests easier to use and more accurate as well as also led to more precise as well as more timely reports. Development in database management tools and wide acceptance of point-of-care (POC) testing solutions will also drive the market. Lack of skilled and certified professionals will hamper the Clinical laboratory services market as which further creates new opportunities for clinical laboratory services with growing adoption of digital pathology platforms. Such policies support Clinical Laboratory Services market growth in the forecast period to 2027.

This clinical laboratory services market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Clinical Laboratory Services Market Scope and Market Size

Global clinical laboratory services market is segmented of the basis of specialty, provider and application. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on specialty, the market is segmented into clinical chemistry testing, microbiology testing, hematology testing, immunology testing, cytology testing, genetic testing and drugs of abuse testing. The clinical chemistry testing segment is dominating the market due to the growing cases of chronic diseases such as liver diseases, cardiovascular diseases and blood disorders which are increasing the demand to use clinical chemistry services. Additionally, the increasing demand of point of care testing solutions which is used for the fast diagnosis of the disease is expected to help the market to growth significantly.

Rising demand of clinical laboratory services across the world is one of the prominent factors for increasing demand of clinical chemistry testing. For instance, yearly in the U.K., the usually citizen has 14 tests completed by a laboratory specialist. However in the U.S., laboratory testing is the only highest-volume medical activity and approximately 13,000 million tests are performed per year. Hence, this factor has led the patients to shift towards clinical chemistry testing because it offers a wide range of tests which are performed in the clinical laboratory testing. In the current scenario the technological advancements boost the patients reach to laboratory testing, which is becoming gradually more precise and affordable. For instance, point-of-care testing (POCT) is regularly applied in hospitals and other healthcare practices, so the patients not need to travel to the clinical laboratories for testing. The increasing use of point-of-care testing has reduced demand tests which are conventionally executed at industry laboratories.

Rising demand of early and accurate disease diagnosis across the globe is one of the prominent factors for an upsurge demand of clinical laboratory services. For instance, in 2018, World Health Organization projected that projected that an estimated 1.8 million new cases and almost 861,000 deaths occur due to colorectal cancer (CRC). This factor has increased the number of clinical laboratories around the globe as Delays in accessing cancer care are very common in the late-stage presentation, especially in lower vulnerable populations and resource settings.

Based on provider, the market is segmented into independent & reference laboratories, hospital-based laboratories, nursing and physician office-based laboratories. The hospital-based laboratories segment is dominating the market due to increasing cases of injuries in the hospitals which leads to the high patient volumes and high test demand. Additionally, the rising inclination of retail clinics for disease monitoring is expected to positively impact in the demand of hospital-based laboratories. Competences of hospitals for acquiring novel technologies and hiring of trained professionals in the disease testing units has created an opportunity for the highest revenue generation. Additionally, the clinical labs are more crucial part of any hospital.

Based on application, the market is segmented into drug discovery related services, drug development related services, bioanalytical & lab chemistry services, toxicology testing services, cell & gene therapy related services, and preclinical & clinical trial related services and other clinical laboratory services. Bioanalytical & lab chemistry services segment is dominating the market because bioanalysis is an important factor in drug discovery and development. It is established that bioanalysis is a vital part of the pharmacokinetic/pharmacodynamic categorization of a novel chemical entity from its discovery and in different phases of drug development including all preclinical and clinical stages. Additionally, lab chemistry services provide support in the chemical analysis including elemental analysis, failure analysis and project analysis.

Clinical Laboratory Services Market Country Level Analysis

The global clinical laboratory services market is analysed and market size information is provided by country by specialty, provider and application as referenced above.

The countries covered in the clinical laboratory services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, South Africa, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil and Rest of South America as part of South America.

Country Level Analysis, By Provider

North America dominates the clinical laboratory services market as the U.S. is leader in clinical laboratory services. In North America due to better advancement in products and services, this region is dominating the clinical laboratory services. North America accounts higher healthcare expenditure, especially in U.S. Asia-Pacific is growing with the highest CAGR due to increase in medical tourism as well as increase in population. Numbers of companies in emerging countries are increasing due to increase in demand for disease diagnosis in clinics, hospitals and other areas. Additionally, the increasing number of healthcare expenditure and increasing number of hospitals and clinical diagnostic laboratories in China and India upsurge demand of clinical laboratory services. The Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing infectious diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by laboratory for Clinical Laboratory Services and New Technology Penetration

Global clinical laboratory services market also provides you with detailed market analysis for every country growth in life science industry with clinical laboratory services demand impact of technological development in laboratory services and changes in regulatory scenarios with their support for the clinical laboratory services market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Clinical Laboratory Services Market Share Analysis

Global clinical laboratory services market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global clinical laboratory services market.

Many business expansion and developments are also initiated by the companies worldwide which are also accelerating the growth of global clinical laboratory services market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for Clinical Laboratory Services through expanded model range.

Customization Available:Global Clinical Laboratory Services Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-clinical-laboratory-services-market&rp

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Visit link:
Clinical Laboratory Services Market - Detailed Analysis of Current and Future Industry Figures till 2027 | Global Players Mayo Foundation for Medical...

UAE hails success of first bone marrow transplant – The National

The UAE is celebrating the success of its first bone marrow transplant.

Typically used to treat patients with blood and cancer disorders , the landmark procedure was carried out on a patient with multiple myeloma, a form of blood cancer.

While cancer is the third-highest cause of death across the Emirates, many Emirati citizens and residents have sought treatment abroad for cell therapy and regenerative medicine.

News of the successful transplant, which was the result of collaboration between Abu Dhabi Stem Cells Centre and Sheikh Khalifa Medical City, represents a major breakthrough for cancer patients living in the UAE who can now seek treatment closer to home to remain with family.

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

The doctors and researchers at Abu Dhabi Stem Cell Centre who were involved in the development of a potential Covid-19 treatment. CourtesyAbu Dhabi Stem Cell Centre

The milestone announcement comes as the centre launched the Abu Dhabi Bone Marrow Transplant programme on Monday.

"It fills us with great pride to be part of a first for the country and to make such a life-saving treatment available and accessible to those who need it here," said Dr Fatima Alkaabi, executive Director of the Abu Dhabi Bone Marrow Transplant programme.

"We are very grateful for the support and collaboration of SKMC in making this opportunity possible."

Bone marrow transplants are one of the most established stem cell-based therapies in the treatment of cancer, particularly blood cancers.

The unique procedure developed by the centre involved harvesting peripheral blood stem cells from the patient, who then underwent high-dose chemotherapy to eradicate all cancerous cells and most of the bone marrow.

The harvested stem cells were then infused back into the bloodstream, where they restore the destroyed cells and over the course of two weeks restart the production of healthy non-malignant blood cells.

"The patient is basically without an immune system while waiting for the transfused cells to take effect and must remain in isolation under the strictest infection control guidelines," said Dr Yendry Ventura, general manager of the stem cell centre and Abu Dhabi bone marrow transplant programme director.

"Since we are still in the midst of a global pandemic, we took additional precautions to ensure the best outcome possible for all involved."

Abu Dhabi Stem Cells Centre has been a driving force behind medical research in the country, including playing a key role in the ongoing fight against Covid-19.

Earlier last month, the team announced the results of the trial of its treatment for Covid-19 patients, branded UAECell19.

After opening in December, the centre has already received international press coverage over to its research into a treatment for the virus.

Their groundbreaking work has involved taking stem cells from a patients blood and returning them, via a nebuliser, as a fine mist to the lungs.

There they help regenerate lung cells and improve the body's immune response by preventing an overreaction to the infection that can damage healthy cells.

Updated: July 27, 2020 05:14 PM

Read more here:
UAE hails success of first bone marrow transplant - The National

Drug target for aggressive breast cancer found by team of UK and US scientists – iNews

The scientists said they were excited by their findings (Photo: ERIC PIERMONT/AFP/Getty)

A team of British and American scientists have discovered a way to slow the growth of breast cancer stem cells in the lab, which could eventually lead to combination drug therapies on previously untreatable forms of the disease.

Around three quarters of women who have breast cancer have what are known as oestrogen receptor positive tumours. Some breast cancer cells have receptors that bind to the hormone oestrogen and depend on it to grow. Though anti-oestrogen drugs such as tamoxifen and fulvestrant are able to prevent reoccurrence in most of these breast cancers, tumours reoccur in 1 out of 4 cases.

Many of the women relapse after several years, because some of the cancer cells remain after treatment. The cells, called cancer stem cells, lay dormant in the body and cannot be targeted by anti-oestrogen therapies.

Scientists have now found that cancer stem cells resistant to anti-oestrogen drugs express an immune system-related receptor, called interleukin 1 receptor. They also found that Anakinra, a drug used to treat rheumatoid arthritis, was able to reduce the ability of the cancer stem cells to grow.

However, the team said further research in animals and humans is needed before they can confirm if drugs targeting interleukin 1 receptor could be used as an effective treatment.

Scientists from the Universities of Michigan, Liverpool and Edinburgh were closely involved in the study led by Dr Bruno Simes and Professor Rob Clarke from The University of Manchester

Dr Simes said: Resistance to anti-oestrogen therapies in breast cancer patients is a major problem and one which cancer scientists have been trying to address for many years. Many drugs have been investigated by scientists as a possible combination therapy taken with anti-oestrogen therapies and we are still searching for a solution for these patients.

However, most of these drugs target actively dividing cells whereas we are trying to also target cells that are in a dormant state. So we hope that these women who have increased numbers of cancer stem cells and do not respond to currents treatment could one day benefit from combination therapy.

Theres a very long way to go before we can say if this approach will help these women but we are excited by our findings.

The study is published in the journal Stem Cell Reports.

Justin Stebbing, professor of cancer medicine and medical oncology at Imperial College London, said: Stem cells represent a very important target to understand better and eradicate, because they are responsible for some of the most worrying aspects of cancer, such as its ability to regrow, or be resistant to treatment. They are also a rare population but this laboratory research shows that cancer stem cells have on their surface a protein that we have a drug for interestingly one that is being trialled in Covid-19 too.

Hopefully, we can in the future link this laboratory work to research in women in the clinic, helping to reduce recurrence rates by eradicating rare stem cell populations that contribute to recurrence.

Baroness Delyth Morgan, chief executive at Breast Cancer Now, which helped fund the study, said: Its promising that targeting this protein [interleukin-1 receptor] may help reduce the growth of breast cancer stem cells, which are thought to be central to the disease spreading around the body, where it becomes incurable.

The development of resistance to hormone therapies remains a major challenge in the clinic. With around 11,500 women still dying from breast cancer each year in the UK, we urgently need to find new ways to prevent the disease spreading and to treat it more effectively when it does.

This exciting discovery highlights the importance of research to understand the molecular detail of how breast cancer spreads, and of investigating the potential of existing drugs to try to stop it. In particular, these findings offer further evidence that arthritis drugs such as Anakinra may be useful additions in treating breast cancer, and we hope further research can now help us fully understand their potential and whether and how they might work as a cancer treatment.

Excerpt from:
Drug target for aggressive breast cancer found by team of UK and US scientists - iNews

Scientists discover why coronavirus patients lose sense of smell and offer hope to those who havent got it – The Scottish Sun

THE KEY symptoms of coronavirus are now widely known as a new and persistent cough, a high temperature and a loss of taste and smell.

But many have been left mystified as to why the respiratory infection would prevent someone from being able to smell.

Read our coronavirus live blog for the latest news & updates

2

Now, scientists say they have the answer - and it's promising news if you're someone who still hasn't had their sense of smell back yet.

A team of experts at Harvard Medical School have identified the cell group which is most vulnerable to Covid-19.

They found the neurons that detect and transmit the sense of smell to the brain are not part of the vulnerable cells.

Researchers did however discover that the ACE 2 receptor protein that Covid uses to enter human cells is found in cells that provide metabolic and structural support.

Non neural cells are found in the central nervous system.

2

The experts said that their research suggests that it is these cells that are responsible for anosmia (loss of taste and smell) in Covid-19 patients.

Writing in Science Advancessenior study author Sandeep Robert Datta said: "Our findings indicate that the novel coronavirus changes the sense of smell in patients not by directly infecting neurons but by affecting the function of supporting cells.

"I think it's good news, because once the infection clears, olfactory neurons don't appear to need to be replaced or rebuilt from scratch."

They say that it means most people who develop anosmia due to Covid-19 will be able to regain their senses.

Anosmia is when you lose your sense of smell, which can be due to a number of different reasons.

The most common include:

It's estimated 6,000 people in the UK are born without a sense of smell and it can be diagnosed by doctors by usingacetylcysteinetests.

Often the condition can be unpleasant and affect your enjoyment of food.

It may go away in weeks or months by itself, but there are certain things you can do to alleviate it.

This includes rinsing the inside of your nose with a salt water solution, if your loss of smell has been caused by an infection or allergy.

You can also pick up sachets and a device from some pharmacies which can help you make a salt water solution.

The findings come after an alternative study found that one in ten coronavirus patients who lose their sense of taste and smell will not get it back.

Researchers compiled their data from Italian patients and found that 49 per cent had fully regained their sense of smell or taste after recovering from the virus.

This is while just 40 per cent reported improvements and 10 per cent said their symptoms had worsened.

Meanwhile analysis of electronic health records found that coronavirus patients are 27 times more likely to have a loss of smell but are 2.2 to 2.6 times more likely to have other respiratory difficulties compared to non Covid patients.

Datta and the team at Harvard looked to how a loss of sense and smell is altered in patients with Covid-19.

They found that cells that wrapped around sensory neurons (setentacular cells) provided metabolic support.

While basal cells helped regenerate after they were damaged.

Theolfactory epithelium is found in the nasal cavity and researchers found that these expressed higher levels of ACE 2 protein compared with resting stem cells.

Revealed

I may look sexy stripping, but usually l think about toast

The authors said that anosmia in Covid-19 patients could arise from a loss of supporting function in the olfactory epithelium which indirectly causes changes to olfactorysensory neurons.

Datta added: "Anosmia seems like a curious phenomenon, but it can be devastating for the small fraction of people in whom it's persistent.

"It can have serious psychological consequences and could be a major public health problem if we have a growing population with permanent loss of smell."

The team added that the research will offer hope to those who have not yet got their senses back as they claim it does not cause permanent damage.

Don't miss the latest news and figures - and essential advice for you and your family.

To receive The Suns Coronavirus newsletter in your inbox every tea time,sign up here.

To follow us on Facebook, simplyLike our Coronavirus page.

Get Britains best-selling newspaper delivered to your smartphone or tablet each day find out more.

See the original post:
Scientists discover why coronavirus patients lose sense of smell and offer hope to those who havent got it - The Scottish Sun

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update – Yahoo Finance

NEW YORK, July 27, 2020 /PRNewswire/ --BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2020, and provide a corporate update, at 8:00 a.m., Eastern Daylight Time (EDT), on Wednesday, August 5 2020.

On the call, BrainStorm CEO Chaim Lebovits will present a corporate update, including details on the timeline for the data readout of the Company's Phase 3 pivotal trial studying the safety and efficacy of NurOwn (MSC-NTF cell) in people with ALS. In addition, Dr. Revital Aricha. Brainstorm's Vice President of Research and Development, will provide an R&D update including recently announced data from the Company's groundbreaking preclinical study evaluating NurOwn-derived exosomes for the treatment of COVID-19 ARDS.

Thereafter, senior management officers will join the call for a Q&A session. Participants are encouraged to submit their questions prior to the call by sending them to:q@brainstorm-cell.com. Questions should be submitted by5:00 p.m. EDT,Monday, August 3, 2020.

Teleconference Details BRAINSTORM CELL THERAPEUTICS 2Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:

Toll Free: 877-407-9205 International: 201-689-8054

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website atwww.ir.brainstorm-cell.comand clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Replay Number:

Toll Free: 877-481-4010 International: 919-882-2331 Replay Passcode: 36017

Teleconference Replay Expiration:

Wednesday, August 19, 2020

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received acceptance from theU.S. Food and Drug Administration(FDA) to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS) and initiated enrollment inMarch 2019.

AboutBrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment inMarch 2019. For more information, visit the company's website atwww.brainstorm-cell.com.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhD Chief Financial Officer BrainStorm Cell Therapeutics Inc. Phone: +1-862-397-1860 pshah@brainstorm-cell.com

Media:Paul Tyahla SmithSolve Phone: +1-973-713-3768 Paul.tyahla@smithsolve.com

View original content:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-announce-second-quarter-financial-results-and-provide-a-corporate-and-rd-update-301100141.html

SOURCE Brainstorm Cell Therapeutics Inc

Go here to read the rest:
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update - Yahoo Finance